Autres langues ExpreS2ion Biotech Holding AB

Actions

EXPRS2

SE0008348262

Temps Différé Nasdaq Stockholm Autres places de cotation 16:20:31 16/05/2024			Varia. 5j.	Varia. 1 janv.
1,44 ^SEK	0,00%		-2,04%	-31,75%

16/04	ExpreS2ion annonce l'achèvement de l'étude de sécurité GLP pour le candidat vaccin ES2B-C001 (HER2-VLP) contre le cancer du sein	CI
21/02	La JV d'ExpreS2ion Biotech obtient 10 millions d'euros suite à l'achèvement par Bavarian Nordic de l'essai clinique du vaccin COVID-19	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ExpreS2ion Biotech : Interim report for January – March 2024 (Q1)	08:42
ExpreS2ion announces financial results for the first quarter of 2024	08:31
ExpreS2ion to present in spring investor events	15/05
ExpreS2ion Biotech : Annual report 2023 including Auditor’s report	08/05
ExpreS2ion annual report for 2023 published	08/05
Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)	03/05
ExpreS2ion announces a rights issue of units of approximately SEK 60 million	02/05
ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS	23/04
ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023	16/04
ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate	16/04
ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	16/04
ExpreS2ion to present in investor and R&D events in March	15/04
ExpreS2ion to present in investor and R&D events in March	29/02
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	21/02
ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine	21/02
ExpreS2ion announces financial results for the fourth quarter and full-year 2023	08/02
ExpreS2ion to present in Redeye Fight Cancer event and the Bio Innovation Leaders Summit	22/01
ExpreS2ion to present new Nipah virus vaccine project in upcoming webcast	12/12
Pareto Securities publishes research report	04/12
ExpreS2ion Biotech Unit Secures EUR8 Million Grant for Virus Vaccine Project; Shares Soar	01/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ExpreS2ion Biotech Holding AB

Actions

EXPRS2

SE0008348262

Autres langues

Filtres